0001209191-21-039810.txt : 20210611 0001209191-21-039810.hdr.sgml : 20210611 20210611161017 ACCESSION NUMBER: 0001209191-21-039810 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210610 FILED AS OF DATE: 20210611 DATE AS OF CHANGE: 20210611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Beaurang Pierre CENTRAL INDEX KEY: 0001817226 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39398 FILM NUMBER: 211011371 MAIL ADDRESS: STREET 1: C/O NURIX THERAPEUTICS, INC. STREET 2: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nurix Therapeutics, Inc. CENTRAL INDEX KEY: 0001549595 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270838048 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: (415) 660-5320 MAIL ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: Nurix, Inc. DATE OF NAME CHANGE: 20120509 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-10 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001817226 Beaurang Pierre C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 0 1 0 0 Chief Business Officer Common Stock 2021-06-10 4 M 0 7500 1.11 A 11830 D Common Stock 2021-06-10 4 S 0 6000 29.1469 D 5830 D Common Stock 2021-06-10 4 S 0 1100 30.0051 D 4730 D Common Stock 2021-06-10 4 S 0 400 30.9037 D 4330 D Common Stock 116666 I By Trust Employee Stock Option (right to buy) 1.11 2021-06-10 4 M 0 7500 0.00 D 2027-02-01 Common Stock 7500 21562 D This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $28.64 and the highest price at which shares were sold was $29.62. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Represents the weighted average sale price. The lowest price at which shares were sold was $29.67 and the highest price at which shares were sold was $30.57. Represents the weighted average sale price. The lowest price at which shares were sold was $30.765 and the highest price at which shares were sold was $30.95. The Reporting Person is a trustee of the Beaurang-Sligh Family Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. The option is fully vested. /s/ Christine Ring, as Attorney-in-Fact for Pierre Beaurang 2021-06-11